Pancreatic Cancer
Clinical research in advanced pancreatic adenocarcinoma and metastatic pancreatic cancer, with interest in treatment strategies for tumors carrying KRAS p.G12C alterations and DNA damage repair gene changes.
- Olaparib with durvalumab
- Sotorasib with first-line chemotherapy
- Metastatic pancreatic cancer
The sponsor’s pancreatic cancer portfolio centers on systemic treatment options for locally advanced and metastatic disease.
Colorectal Cancer with BRAF Alterations
Research in BRAF V600E mutated and microsatellite stable advanced colorectal cancer, including tumors that are initially resectable or potentially resectable and settings where radical treatment may be pursued.
- Cetuximab with encorafenib and binimetinib
- Radical treatment of primary and metastatic lesions
- BRAF V600E mutated MSS aCRC
This area reflects a focus on targeted approaches for molecularly defined colorectal tumors.
Metastatic Colorectal Cancer
Clinical interest in metastatic colorectal cancer with wild-type RAS and primary left-sided disease, using chemotherapy sequences combined with biologic therapies.
- FOLFOX and FOLFIRI sequencing
- Panitumumab
- Bevacizumab
The trials in this field examine treatment selection across first-line and subsequent therapy combinations.
Molecularly Targeted Oncology
Across its studies, the sponsor is involved in precision oncology for gastrointestinal malignancies, with emphasis on biomarker-defined treatment selection and targeted drug combinations.
- Biomarker-driven patient selection
- Targeted therapy combinations
- Gastrointestinal cancer
Its research activity spans pancreatic and colorectal tumors in settings where molecular profiling informs therapeutic choice.
